Provided by Tiger Trade Technology Pte. Ltd.

YD Bio Ltd

4.00
+0.10002.56%
Post-market: 4.000.00000.00%19:30 EDT
Volume:819.27K
Turnover:3.17M
Market Cap:282.09M
PE:-34.19
High:4.19
Open:3.93
Low:3.61
Close:3.90
52wk High:25.00
52wk Low:1.70
Shares:70.52M
Float Shares:16.23M
Volume Ratio:1.27
T/O Rate:5.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1170
EPS(LYR):-1.2901
ROE:-42.69%
ROA:-25.43%
PB:42.80
PE(LYR):-3.10

Loading ...

YD Bio CEO Ethan Shen Acquires 3,100 Common Shares for $12,183

Reuters
·
Sep 11

YD Bio CEO Ethan Shen Acquires 18,378 Shares Valued at $67,246.26

Reuters
·
Sep 09

YD Bio Management Commentary Cites Larger Drug, Medical Product Orders Driving H1 2026 Revenue up to $0.8 Million

Reuters
·
Sep 01

YD Bio 1H FY26 Net Income Swings to USD 6.7 Million; Revenue Rises 315% to USD 846,501

Reuters
·
Sep 01

Yd Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

THOMSON REUTERS
·
Sep 01

Press Release: YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

Dow Jones
·
Sep 01

NASDAQ Trade Halt Volatility Trading Pause at 11:28 Am

Reuters
·
Aug 31

NASDAQ Trade Halt Volatility Trading Pause at 03:43 Pm

Reuters
·
Aug 29

YD Bio Reports Peer-Reviewed Nutrients Publication on Omega-3, Vitamins D3 and K2 "heart-Brain-Bone" Axis

Reuters
·
Aug 25

Yd Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute

THOMSON REUTERS
·
Aug 11

YD Bio Highlights Peer-Reviewed Computational Study Nominating Keratoconus Regenerative Therapy Targets

Reuters
·
Aug 04

YD Bio Launches Cancer Testing Pilot with Numia Health in Canada

Reuters
·
Jul 28

YD Bio Wins Rhode Island, Pennsylvania Lab Licenses, Expanding U.S. Footprint to 46 States

Reuters
·
Jul 02

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:48 PM

Reuters
·
Jun 04

Yd Bio Limited Reports Full Year 2025 Financial Results

THOMSON REUTERS
·
May 01

YD Bio FY25 net loss widens to $8.3 million; revenue rises 17% to $596,817

Reuters
·
May 01

YD Bio Ltd trading halted, volatility trading pause

TIPRANKS
·
Apr 08

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:56 PM

Reuters
·
Apr 08

YD Bio files Form 3 as director Kochi Chang reports no beneficial ownership

Reuters
·
Apr 02

YD Bio files Form 3; director Jerry Yin-Chia Lee reports no securities owned

Reuters
·
Mar 31